Matthew P Goetz MD

Clinical Trials

• Gemcitabine and Irinotecan in Treating Patients With Cancer of Unknown Primary Start of enrollment: 2004 Feb 01

  Completed

  Phase 2

• Irinotecan, Oxaliplatin, and Capecitabine in Treating Patients With Unresectable Solid Tumors Start of enrollment: 2003 Nov 01

  Completed

  Phase 1

• Irinotecan, Fluorouracil, Leucovorin, and Oxaliplatin as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer Start of enrollment: 2004 Mar 01

  Completed

  Phase 2

• Liposomal SN-38 in Treating Patients With Small Cell Lung Cancer

  Withdrawn

  Phase 2

• Irinotecan and Cetuximab in Treating Patients With Metastatic Breast Cancer Start of enrollment: 2006 Feb 01

  Completed

  Phase 2

• AFP464 in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery Start of enrollment: 2006 Jul 01

  Completed

  Phase 1

• Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer Start of enrollment: 2007 May 01

  Completed

  Phase 2

• Percutaneous Cryoablation in Treating Patients With Painful Bone Metastases Start of enrollment: 2003 Nov 01

  Completed

  Not Applicable

• Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline Start of enrollment: 2011 Mar 16

  COMPLETED

• Breath Test for Women Receiving Tamoxifen in the Prevention or Treatment of Breast Cancer Start of enrollment: 2009 May 01

  Terminated

• Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary Start of enrollment: 2009 Sep 01

  Completed

  Phase 2

• Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast Cancer Start of enrollment: 2011 Mar 25

  ACTIVE_NOT_RECRUITING

  PHASE1

• Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer Start of enrollment: 2011 May 02

  ACTIVE_NOT_RECRUITING

  PHASE1

• Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer Start of enrollment: 2012 Dec 11

  Completed

  Phase 2

• S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Start of enrollment: 2013 Sep 12

  ACTIVE_NOT_RECRUITING

  PHASE3

• PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer Start of enrollment: 2013 Apr 10

  ACTIVE_NOT_RECRUITING

  PHASE2

• Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer Start of enrollment: 2013 Jan 01

  Terminated

  Phase 2

• Breast Cancer Genome Guided Therapy Study (BEAUTY)

  ACTIVE_NOT_RECRUITING

• Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer Start of enrollment: 2019 Aug 28

  ACTIVE_NOT_RECRUITING

  PHASE2

• Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer Start of enrollment: 2020 Jan 10

  RECRUITING

  PHASE2

• Development of Patient Derived Xenografts (PDX) in Patients With Breast Cancer Start of enrollment: 2021 Jan 13

  Recruiting

• Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss Start of enrollment: 2020 Jun 08

  ACTIVE_NOT_RECRUITING

  PHASE3

  Roles: Contact

• Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation Start of enrollment: 2023 Oct 31

  RECRUITING

  PHASE3

  Roles: Contact

• Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis Start of enrollment: 2025 Jan 30

  RECRUITING

  PHASE1, PHASE2

  Roles: Contact, Principal Investigator

• Join now to see all